You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated Microarray Printing and Detection System

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

    SBC: PAPGENE, INC.            Topic: NCI

    This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Yeast based Immunotherapy against Clostridium difficile Infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Strategies to Improve Production of a Full Length Native HIV Env Spike

    SBC: CODEX BIOSOLUTIONS            Topic: R

    Project Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Serotype independent therapeutic vaccine for Streptococcus pneumoniae

    SBC: Integrated Biotherapeutics, Inc.            Topic: R

    In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Tools to Measure Non Receptor Tyrosine Kinase Activities for Drug Discovery and Biomarker Analysis

    SBC: Kinasense LLC            Topic: 102

    Project Abstract Advanced cell based technologies for kinase activity profiling are needed for earlier identification of next generation kinase inhibitors and to enable clinical evaluation of kinase activity biomarkers The long term goal of this proposal is to generate targeted kinase activity tests compatible with viable cells from patient derived samples The objectives in this proposal work t ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: NCI

    Radiopharmaceutical therapyRPTis an emerging cancer treatment that delivers radiation directly to cancer cellsThe recent FDA approval ofRa Xofigotmfor resistant metastatic prostate cancer and its commercial success provides an example of the therapeutic and commercial potential of this modalityIn additiondrug companies have large libraries of targets and targeting moleculesProgress in chelators an ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    Significance Despite decreases in the overall number of new breast cancer BC cases reported in the US annually there are still about BC deaths annually from metastatic breast cancer MBC Thus the ability to monitor MBC is important to determine disease status and therapy response While the gold standard imaging is expensive time consuming and slow to detect disease response o ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Developing specific rapid and cost effective immunoassays for Zika detection

    SBC: MEDIOMICS, LLC            Topic: R

    This proposal aims to develop highly specific rapid and cost effective immunoassays to detect Zika virus ZIKV infection ZIKV is a single stranded RNA virus in the Flaviviridae family that is transmitted to humans through infected mosquitos blood transfusions and sexual contact As of June around Zika Virus disease cases have been estimated in Brazil alone Recently ZIKV has be ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government